ORAL BISPHOSPHONATE THERAPY FOR ADULTS WITH OSTEOGENESIS IMPERFECTA

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本提案描述了一项评价口服双膦酸盐治疗成骨不全（OI）成人的疗效的研究。OI是一种遗传性胶原蛋白合成障碍。受影响的人骨密度低，经历多处骨折和进行性骨畸形。迄今为止，对于这种使人衰弱的病症还没有有效的治疗方法。据报道，在少数接受双膦酸盐治疗的患者中，骨密度和骨折发生率得到改善。口服双膦酸盐的疗效尚未确定。我们将描述口服双膦酸盐治疗的变化，并比较每日与每周口服双膦酸盐治疗成人OI的疗效。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This proposal describes a study to evaluate the efficacy of oral bisphosphonate therapy for adults with Osteogenesis Imperfecta (OI). OI is a heritable disorder of collagen synthesis. Affected persons have low bone mineral density and experience multiple fractures and progressive bony deformity. To date, no effective therapy exists for this debilitating condition. Improvements in bone mineral density and in fracture rates in a small number of patients treated with bisphosphonates have been reported. The efficacy of oral bisphosphonate has not been established. We will characterize the changes effected by oral bisphosphonate therapy and compare the efficacy of daily versus weekly dosing of oral bisphosphonate in adults with OI.